|
a fully human version of Rituxan will be FDA approved (Ofatumab, Arrixa) from GSK-Genmab.
Approval should lead to a drop in price for BIIB stock. I also personally heard a Genentech sales person say that DNA (Roche) management is expecting a significant drop in Rituxan sales once the Genmab product gets approved. Royalities from Rituxan is BIIB's biggest moneymaker. BIIB may use the FDA approval as the reason to raise the offer for Facet. Rating :
 (No ratings) |
 |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
Messages in Topic
| Subject | Author | Rating | Time of Post (ET) | ||
|---|---|---|---|---|---|
|
Sometime in the next two weeks
|
trufflesdri... | Not rated | 12-Oct-09 11:42 am | ||
|
I don't think that the impact from Ofatumumab in C...
|
biopharmabu... | Rate it | 16-Oct-09 04:57 pm | ||
|
FDAnews Drug Daily Bulletin
Oct. 19, 2009 | Vol....
|
broadalyst
Online Now
|
Rate it | 20-Oct-09 02:49 pm | ||
|
Fully human Rituxmab approved by FDA on 10/26.
|
trufflesdri... | Rate it | 28-Oct-09 02:06 pm |
|
Page
1
of about
1
First
| < Prev
| Next >
| Last
|
0.06